Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia
January 7, 2021
January 7, 2021
MedinCell announces the resume of listing of its shares on Euronext Paris as of the opening of the stock exchange tomorrow
January 7, 2021
January 7, 2021
Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin
December 17, 2020
December 17, 2020
Live webcast of the Shareholders’ Meeting on Tuesday, December 15, 2020
December 11, 2020
December 11, 2020
MedinCell publishes its first-half 2020/2021 financial results (April – September 2020): operating expenses and portfolio development in line with expectations
December 9, 2020
December 9, 2020
MedinCell publishes its financial results and activity report for the first half of 2021-2022
December 8, 2020
December 8, 2020
Videoconference and publication of the 2020-2021 Half-Year Results, on December 9, 2020
December 2, 2020
December 2, 2020
First long-acting injectable (LAI) antipsychotic using MedinCell’s technology reaches Phase 3 clinical study primary completion date
November 12, 2020
November 12, 2020
Convening of the General Assembly: Proposal for the appointment of Elisabeth Kogan to the Supervisory Board
November 9, 2020
November 9, 2020
MedinCell initiates the first clinical trial of its Covid-19 prevention program
